Related Experiment Video
Updated: Jun 6, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
Published on: February 9, 2011
Successful treatment of meticillin-resistant Staphylococcus aureus bacteraemia in a neonate using daptomycin
Abid Hussain1, Venkatesh Kairamkonda2, David Richard Jenkins1
1Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
Abstract:
Daptomycin is licensed for the management of Staphylococcus aureus infections in adults, including those caused by meticillin-resistant S. aureus (MRSA). Few data exist on paediatric use or dose guidance in neonates. We report the case of a neonate with MRSA bacteraemia successfully managed with daptomycin. Dose requirements were substantially higher than those recommended for adults.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Staphylococcal Skin Infections
Mechanism of Antibiotic Resistance in MRSA
Acute Pyelonephritis II: Diagnostic Studies and Management
